One Mission: Deliver Treatments and Cures to End Charcot-Marie-Tooth (CMT).

Finding a Cure at CMTRF:

Where We Started, How Far We Have Come and Where We are Going

Charcot-Marie-Tooth disease was identified in 1886. Yet for the next 120 or so years there was no organized effort to help find an effective treatment or, better yet, a cure – even though CMT affects one in 2,500 people (about the same prevalence as multiple sclerosis) including 150,000 Americans and nearly 3 million people around the world.

More has been accomplished in the past five years toward finding effective treatments and a possible cure than ever before.  There is light at the end of the tunnel.  Read more.

What is CMT?

Charcot-Marie-Tooth (CMT) is a genetic nerve disease with over 100 known genetic causes. Onset can be at birth or later in life and is characterized by degeneration of motor nerves and loss of sensation in the feet, hands, legs and arms. CMT is a progressive disease that can lead to severe disability or even death.

Too many

Nearly three million people of every age, race and ethnicity are living with CMT. This is the same prevalence as multiple sclerosis (MS) and ten times the prevalence of amyotrophic lateral sclerosis (ALS).


Currently there is no cure for CMT, and there are no effective treatments.


90¢ of Every Donated Dollar Funds Research

Funding Research for CMT

The CMT Research Foundation (CMTRF) is the only organization focused solely on delivering treatments and cures for CMT. The CMT Research Foundation is a 501(c)(3) charitable organization. Learn more about CMT Research we fund.


We are funding the most promising and efficient research aimed exclusively toward drug delivery.

Results Driven

We foster strategic partnerships with academia and industry stakeholders to deliver results.

The climate for the delivery of treatments for CMT is ideal for three reasons: there is a high prevalence of people living with CMT; there are new incentives from the FDA to focus on rare, genetic diseases; and early discovery work is robust. Industry partners know these facts and are eager to deliver treatments for CMT.

Susan Ruediger

Founder and CEO, CMT Research Foundation

Our Credo

The CMT Research Foundation is committed to doing our part to end CMT.
Our work is guided by three core commitments:

Clear Strategy

Our single focus is to deliver treatments and cures for CMT. This laser focus ensures that our time, attention and funds go straight to translational research aimed only at drug delivery.


By limiting overhead and eliminating redundant projects, CMT Research Foundation stretches every dollar to deliver results faster.


Through clear and regular reporting of research projects funded by CMT Research Foundation, all supporters are assured that their donations are being used efficiently and effectively.